Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Antiparkinson Agents (therapeutic use) And NotAlexis Brice

List of bibliographic references

Number of relevant bibliographic references: 51.
Ident.Authors (with country if any)Title
000071 Alexandre Krainik [France] ; Audrey Maillet ; Vanessa Fleury ; Mehmet Sahin ; Irène Troprès ; Laurent Lamalle ; Stephane Thobois ; Valerie Fraix ; Marjorie Villien ; Jan Warnking ; Pierre Pollak ; Serge Pinto ; Paul KrackLevodopa does not change cerebral vasoreactivity in Parkinson's disease.
000075 Fanny Duval [France] ; Olivier Flabeau ; Julien Razafimahefa ; Umberto Spampinato ; François TisonEncephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome.
000087 Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia TrenkwalderAFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
000145 Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal]The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
000146 Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal]The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
000165 Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche]Milestones in Parkinson's disease therapeutics
000179 Estelle Dellapina [France] ; Angélique Gerdelat-Mas [France] ; Fabienne Ory-Magne [France] ; Laure Pourcel [France] ; Monique Galitzky [France] ; Fabienne Calvas [France] ; Marion Simonetta-Moreau [France] ; Claire Thalamas [France] ; Pierre Payoux [France] ; Christine Brefel-Courbon [France]Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
000198 Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne]Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study
000200 Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche]Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
000202 Martin Köllensperger [Autriche] ; Felix Geser [Autriche] ; Jean-Pierre Ndayisaba [Autriche] ; Sylvia Boesch [Autriche] ; Klaus Seppi [Autriche] ; Karen Ostergaard [Danemark] ; Erik Dupont [Danemark] ; A. Cardozo [Espagne] ; Eduardo Tolosa [Espagne] ; Michael Abele [Allemagne] ; Thomas Klockgether [Allemagne] ; Farid Yekhlef [France] ; Francois Tison [France] ; Christine Daniels [Allemagne] ; Günther Deuschl [Allemagne] ; Miguel Coelho [Portugal] ; Cristina Sampaio [Portugal] ; Maria Bozi [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Anette Schrag [Royaume-Uni] ; Chris J. Mathias [Royaume-Uni] ; Clare Fowler [Royaume-Uni] ; Christer F. Nilsson [Suède] ; H Kan Widner [Suède] ; Nicole Schimke [Allemagne] ; Wolfgang Oertel [Allemagne] ; Francesca Del Sorbo [Italie] ; Alberto Albanese [Italie] ; Maria Teresa Pellecchia [Italie] ; Paolo Barone [Italie] ; Ruth Djaldetti [Israël] ; Carlo Colosimo [Italie] ; Giuseppe Meco [Italie] ; Antonio Gonzalez-Mandly [Espagne] ; Jose Berciano [Espagne] ; Tanya Gurevich [Israël] ; Nir Giladi [Israël] ; Monique Galitzky [France] ; Olivier Rascol [France] ; Christoph Kamm [Allemagne] ; Thomas Gasser [Allemagne] ; Uwe Siebert [Autriche, États-Unis] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry
000231 Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne]Validation of the freezing of gait questionnaire in patients with Parkinson's disease
000235 Caroline Moreau [France] ; Luc Defebvre [France] ; David Devos [France] ; Fabio Marchetti [Italie] ; Alain Destée [France] ; Alessandro Stefani [Italie] ; Antonella Peppe [Italie]STN versus PPN‐DBS for alleviating freezing of gait: Toward a frequency modulation approach?
000240 David Devos [France]Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease
000247 David Maltête [France] ; Nathalie Chastan [France] ; Stéphane Derrey [France] ; Bertrand Debono [France] ; Emmanuel Gérardin [France] ; Romain Lefaucheur [France] ; Bruno Mihout [France] ; Didier Hannequin [France]Microsubthalamotomy effect at day 3: Screening for determinants
000252 Nathalie Chastan [France] ; Manh Cuong Do [France] ; Fabrice Bonneville [France] ; Frédéric Torny [France] ; Frédéric Bloch [France] ; G. W. Max Westby [France] ; Didier Dormont [France] ; Yves Agid [France] ; Marie-Laure Welter [France]Gait and balance disorders in Parkinson's disease: Impaired active braking of the fall of centre of gravity
000260 Paul Sauleau [France] ; Emmanuelle Leray [France] ; Tiphaine Rouaud [France] ; Sophie Drapier [France] ; Dominique Drapier [France] ; Sophie Blanchard [France] ; Gwenolla Drillet [France] ; Julie Péron [France] ; Marc Vérin [France]Comparison of weight gain and energy intake after subthalamic versus pallidal stimulation in Parkinson's disease
000263 Karim Farid [France] ; Igor Sibon [France] ; Dominique Guehl [France] ; Emmanuel Cuny [France] ; Pierre Burbaud [France] ; Michèle Allard [France]Brain dopaminergic modulation associated with executive function in Parkinson's disease
000267 Donald Grosset [Royaume-Uni] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Gianni Pezzoli [Italie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Karen Shaw [Royaume-Uni] ; Esther Cubo [Espagne] ; Pablo Martinez-Martin [Espagne] ; Olivier Rascol [France] ; Laurence Negre-Pages [France] ; Ana Senard [France] ; Johannes Schwarz [Allemagne] ; Karl Strecker [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] ; Matthias Löhle [Allemagne] ; Fabrizio Stocchi [Italie] ; Katherine Grosset [Royaume-Uni]Adherence to antiparkinson medication in a multicenter European study
000285 Christopher G. Goetz [États-Unis] ; Eugene Laska [États-Unis] ; Christine Hicking [Allemagne] ; Philippe Damier [France] ; Thomas Müller [Allemagne] ; John Nutt [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Placebo influences on dyskinesia in Parkinson's disease
000312 Adeline Gallini [France] ; Agnès Sommet [France] ; Anne-Marie Salandini [France] ; Patrick Veyssière [France] ; Jean-Louis Montastruc [France] ; Jean-Louis Montastruc [France]Weight‐loss associated with anti‐dementia drugs in a patient with Parkinson's disease
000314 Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
000317 Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial
000321 Vincent Paillé [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France]Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
000353 Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France]The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
000360 Emmanuel Roze [France] ; Marie Vidailhet [France] ; Nenad Blau [Suisse] ; Lisbeth Birk Moller [Danemark] ; Diane Doummar [France] ; Thierry Billette De Villemeur [France] ; Anne Roubergue [France]Long‐term follow‐up and adult outcome of 6‐pyruvoyl‐tetrahydropterin synthase deficiency
000368 Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardès [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France]Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease
000369 Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni]Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
000377 Andre Machado [États-Unis] ; Ali R. Rezai [États-Unis] ; Brian H. Kopell [États-Unis] ; Robert E. Gross [États-Unis] ; Ashwini D. Sharan [États-Unis] ; Alim-Louis Benabid [France]Deep brain stimulation for Parkinson's disease: Surgical technique and perioperative management
000383 Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France]Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors
000399 Pierre-Olivier Fernagut [États-Unis] ; Imad Ghorayeb [France] ; Elsa Diguet [France] ; François Tison [France]In vivo models of multiple system atrophy
000404 Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
000407 Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Claire Thalamas [France] ; Fabienne Ory [France] ; Isabelle Quelven [France] ; François Chollet [France] ; Jean Louis Montastruc [France] ; Olivier Rascol [France]Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
000424 Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France]Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study
000432 C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie]Levodopa in the treatment of Parkinson's disease: Current controversies
000456 Patrice Péran [France] ; Olivier Rascol [France] ; Jean-François Démonet [France] ; Pierre Celsis [France] ; Jean-Luc Nespoulous [France] ; Bruno Dubois [France] ; Dominique Cardebat [France]Deficit of verb generation in nondemented patients with Parkinson's disease
000460 Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Paul Krack [France] ; Valérie Fraix [France] ; Nadège Van Blercom [France] ; Jing Xie [France] ; Elena Moro [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France]Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease
000465 Annie Lannuzel [France] ; Patrick P. Michel [France] ; Dominique Caparros-Lefebvre [France] ; Jacqueline Abaul ; Reynald Hocquemiller ; Merle Ruberg [France]Toxicity of Annonaceae for dopaminergic neurons: Potential role in atypical parkinsonism in Guadeloupe
000468 Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation
000470 Paul Krack [France] ; Valérie Fraix [France] ; Alexandre Mendes [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France]Postoperative management of subthalamic nucleus stimulation for Parkinson's disease
000471 François Tison [France] ; Farid Yekhlef [France] ; Virginie Chrysostome [France] ; Eric Balestre [France] ; Niall P. Quinn [Royaume-Uni] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS‐III), and disability assessment compared with Parkinson's disease
000482 Luc J. P. Defebvre [France] ; Pierre Krystkowiak [France] ; Jean-Louis Blatt [France] ; Alain Duhamel [France] ; Jean-Louis Bourriez [France] ; Myriame Périna [France] ; Serge Blond [France] ; Jean-Daniel Guieu [France] ; Alain Destée [France]Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease
000508 Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France]Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
000510 Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
000511 E. Apartis [France] ; F. Tison [France] ; P. Arné [France] ; C. P. Jedynak [France] ; M. Vidailhet [France]Fast orthostatic tremor in Parkinson's disease mimicking primary orthostatic tremor
000560 Korczyn [Israël] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Warner H. Poewe [Autriche] ; Olivier Rascol [France] ; Fabrizzio Stocchi [Italie]Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
000561 Rascol [France] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Amos D. Korczyn [Israël] ; Warner H. Poewe [Autriche] ; Fabrizzio Stocchi [Italie]Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study
000584 Derex [France] ; P. Trouillas [France]Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy
000591 Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Montastruc [France]A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
000617 Limousin [France] ; Pierre Pollak [France] ; Abdelhamid Benazzouz [France] ; Dominique Hoffmann [France] ; Emmanuel Broussolle [France] ; Jean Edmond Perret [France] ; Alim-Louis Benabid [France]Bilateral subthalamic nucleus stimulation for severe Parkinson's disease
000619 Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France]A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine
000654 Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Yves Agid [France] ; X. Lataste [Suisse]Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024